Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Josephson Wallack Munshower Neurology PC

Neither a doctor nor a teaching hospital

Research payments

$1,490,870

161 payments

Through program year 2025, Josephson Wallack Munshower Neurology PC is reported as receiving $1,490,870 in research payments, across 161 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $528,567 41
2024 Research $316,563 44
2023 Research $264,392 20
2022 Research $85,460 7
2021 Research $136,895 24
2020 Research $54,766 10
2019 Research $104,226 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $614,306 52 payments
  2. TG Therapeutics, Inc. $548,669 54 payments
  3. Allergan Inc. $171,506 36 payments
  4. Novartis Pharmaceuticals Corporation $85,275 7 payments
  5. Amgen Inc. $61,145 8 payments
  6. EMD Serono, Inc. $6,500 1 payment
  7. AbbVie, Inc. $2,300 2 payments
  8. Janssen Research & Development, LLC $1,169 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab $548,669 54 payments
  2. A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib in Adults With Progressive Ms $490,242 36 payments
  3. Assessing Disease Activity in Minority Patients With Relapsing Multiple Sclerosis Using Ocrelizumab $116,064 15 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $74,298 12 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $48,330 10 payments
  6. A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Chronic Or Episodic Migraine $42,372 9 payments
  7. Ph3 Pediatric CM Study $39,236 4 payments
  8. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $31,666 2 payments
  9. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $27,677 3 payments
  10. A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 MG Subcutaneous Ofatumumab Injected By Pre-Filled Syringe Or Autoinjector in Adult RMS Patients $20,478 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record